![Brian Conner](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Brian Conner
Plus aucun poste en cours
Historique de carrière de Brian Conner
Anciens postes connus de Brian Conner
Sociétés | Poste | Début | Fin |
---|---|---|---|
Synageva BioPharma Corp. /Old/
![]() Synageva BioPharma Corp. /Old/ BiotechnologyHealth Technology Synageva BioPharma's ultimate goal is to improve patient lives by providing access to breakthrough novel, next generation (i.e. significantly improved), and certain follow on protein therapeutics. Synageva's proprietary platform technologies, including SEP™, provide a number of sustainable competitive advantages for developing and commercializing these therapeutics including: high expression levels, more efficient purification processes, significantly reduced costs of production, rapid scalability, and consistency of end product. Its platform has already demonstrated its ability to produce a wide array of human therapeutic proteins including monoclonal antibodies (mAbs), cytokines, and other biotherapeutics. It has multiple compounds in development, including 2 monoclonal antibodies with enhanced ADCC activity, novel therapeutic proteins, and several cytokines including one with unique efficacy advantages. The commercialization strategy for these product candidates is designed to maximize its ability to rapidly develop and bring them to market so that they can address patients' unmet medical needs. The key elements of the strategy are to: 1. Establish partnerships to co-develop and commercialize select product candidates in large specialty markets 2. Independently develop and commercialize select novel product candidates that target high value orphan specialty markets 3. Establish partnerships to express proteins from other companies wanting to leverage the unique glycosylation advantages and other characteristics of the SEP™. | Conseiller Juridique Général | 22/10/2009 | 04/11/2011 |
Saatchi & Saatchi North America LLC
![]() Saatchi & Saatchi North America LLC Advertising/Marketing ServicesCommercial Services Saatchi & Saatchi North America, Inc. provides advertising services. It offers creative advertising services and plans marketing campaigns for advertisers and global companies. The company was founded in 1970 and is headquartered in New York, NY. | Corporate Officer/Principal | - | - |
MERCK & CO., INC. | Corporate Officer/Principal | - | - |
Genzyme Corp.
![]() Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Conseiller Juridique Général | - | - |
Stiefel Laboratories, Inc.
![]() Stiefel Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Stiefel Laboratories, Inc. engages in the manufacture of pharmaceutical products. It offers prescription and non-prescription dermatological and skin care products. The firm research, innovate and develop skin care treatments to health care professionals, patients and consumers. The company was founded in 1847 and is headquartered in Research Triangle Park, NC. | Conseiller Juridique Général | - | - |
Formation de Brian Conner
Drexel University | Undergraduate Degree |
Statistiques
Internationale
Etats-Unis | 7 |
Opérationnelle
General Counsel | 3 |
Corporate Officer/Principal | 2 |
Undergraduate Degree | 1 |
Sectorielle
Health Technology | 5 |
Commercial Services | 2 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
MERCK & CO., INC. | Health Technology |
Entreprise privées | 4 |
---|---|
Synageva BioPharma Corp. /Old/
![]() Synageva BioPharma Corp. /Old/ BiotechnologyHealth Technology Synageva BioPharma's ultimate goal is to improve patient lives by providing access to breakthrough novel, next generation (i.e. significantly improved), and certain follow on protein therapeutics. Synageva's proprietary platform technologies, including SEP™, provide a number of sustainable competitive advantages for developing and commercializing these therapeutics including: high expression levels, more efficient purification processes, significantly reduced costs of production, rapid scalability, and consistency of end product. Its platform has already demonstrated its ability to produce a wide array of human therapeutic proteins including monoclonal antibodies (mAbs), cytokines, and other biotherapeutics. It has multiple compounds in development, including 2 monoclonal antibodies with enhanced ADCC activity, novel therapeutic proteins, and several cytokines including one with unique efficacy advantages. The commercialization strategy for these product candidates is designed to maximize its ability to rapidly develop and bring them to market so that they can address patients' unmet medical needs. The key elements of the strategy are to: 1. Establish partnerships to co-develop and commercialize select product candidates in large specialty markets 2. Independently develop and commercialize select novel product candidates that target high value orphan specialty markets 3. Establish partnerships to express proteins from other companies wanting to leverage the unique glycosylation advantages and other characteristics of the SEP™. | Health Technology |
Stiefel Laboratories, Inc.
![]() Stiefel Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Stiefel Laboratories, Inc. engages in the manufacture of pharmaceutical products. It offers prescription and non-prescription dermatological and skin care products. The firm research, innovate and develop skin care treatments to health care professionals, patients and consumers. The company was founded in 1847 and is headquartered in Research Triangle Park, NC. | Health Technology |
Genzyme Corp.
![]() Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Saatchi & Saatchi North America LLC
![]() Saatchi & Saatchi North America LLC Advertising/Marketing ServicesCommercial Services Saatchi & Saatchi North America, Inc. provides advertising services. It offers creative advertising services and plans marketing campaigns for advertisers and global companies. The company was founded in 1970 and is headquartered in New York, NY. | Commercial Services |
- Bourse
- Insiders
- Brian Conner
- Expérience